Clinical trial
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or…
NCT00238329 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00238329 |
|---|---|
| Title | PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma |
| Official title | Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2b, thalidomide |
| Enrollment | 32 |
| Start date | Jan 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Oct 13, 2005 |
| Last update posted | Apr 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: